Pierre Fabre and Lonza enter into a manufacturing agreement for the W0180 antibody
- Lonza will provide clinical drug manufacturing for W0180, an oncology drug candidate discovered by Pierre Fabré targeting solid tumors, from its filling and finishing center in Stein, Swiss
- Pierre Fabré leverage Lonza’s pharmaceutical expertise and fill and finish capabilities
Toulouse, France, June 15, 2022 /PRNewswire/ — Lonza, a global development and manufacturing partner to the pharmaceutical, biotechnology and nutritional industries, and a French pharmaceutical group Pierre Fabré announced today that the companies have reached a manufacturing agreement.
This collaboration aims to manufacture W0180, an innovative monoclonal antibody discovered by Pierre Fabré targeting the VISTA checkpoint, currently being studied as a single agent and in combination with pembrolizumab in a Phase I clinical trial (NCT04564417) in various solid tumors.
Lonza will provide cGMP pharmaceutical manufacturing services for clinical supply from its fill and finish facility in Stein, Swiss. Lonza’s ability to provide exemplary pharmaceutical development and manufacturing services provides customers with innovative solutions and the ability to provide high quality products for clinical use.
Jean-Luc LowinskiCEO of Pierre Fabre Medical Care, said: “We are delighted to entrust the production of the drug product W0180 to Lonza. Its pharmaceutical product services are well suited to our advanced therapy manufacturing needs. The W0180 will be manufactured at Lonza’s GS Xceed factory.® Expression CHO System, also successfully used for IGF1R and cMet antibodies discovered by Pierre Fabré.”
W0180 is a first-in-class antibody targeting VISTA (V-domain Ig suppressor of T cell Activation). VISTA is a negative checkpoint regulator of the T-cell response. VISTA is expressed in the tumor microenvironment, where its inhibition may enhance anti-tumor immune responses. In addition, an increase in the expression of VISTA has been reported after treatment with anti-PD1/L1 and anti-CTLA4. This confirms that VISTA may play a key role as a mechanism of resistance to currently used immunotherapies. W0180 given to patients as monotherapy or in combination with anti-PD1/L1 therapy has potential in multiple cancer indications, including those with immunosuppressive myeloid infiltrates where the VISTA pathway is expressed.
About Pierre Fabré
The Pierre Fabre group is the second French private health group and the second world manufacturer of dermo-cosmetics. In 2021, it generated 2.5 billion euros in turnover, of which 66% came from international sales. Pierre Fabré employs some 9,500 people worldwide and manufactures more than 95% of its products in France. Its portfolio includes several medical franchises and international brands, including Pierre Fabre Oncologie, Pierre Fabre Dermatologie, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma and Pierre Fabre Oral Care.
In oncology, Pierre Fabré has over 35 years of experience in discovery, development, manufacturing and commercialization, with a portfolio of therapies spanning colorectal, breast, lung cancer, melanoma and pre-cancerous conditions, such as actinic keratosis . by Pierre Fabré innovation and commercialization efforts in oncology focus on targeted therapies, biotherapies and immuno-oncology.
The Pierre Fabre Group is 86% owned by the Pierre Fabre Foundation, a public utility foundation, and secondarily by its own employees through an international employee shareholding plan.
More information on Pierre Fabré to be found on www.pierre-fabre.com, @PierreFabre.
Contact details Pierre Fabre
Oncology Communication Manager
Logo – https://mma.prnewswire.com/media/1836798/Pierre_Fabre_Lonza_Logo.jpg
THE SOURCE Pierre Fabré; lonza